Correspondence 0001387131-23-009025 from Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Date: July 28, 2023 · CIK: 0000887247 · Accession: 0001387131-23-009025
AI Filing Summary & Sentiment
File numbers found in text: 333-273233
Letter
Adamis Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103
July 28, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Adamis Pharmaceuticals Corporation
Registration Statement on Form S-3 (No. 333-273233)
Filed on July 13, 2023
Withdrawal of Request for Acceleration
To Whom it May Concern:
Adamis Pharmaceuticals Corporation (the "Company") hereby requests the withdrawal of our request for acceleration, dated July 26, 2023, of the effective date of the above referenced registration statement as amended (the “Registration Statement”) (File No. 333-273233) that was requested to become effective at 9:00 a.m. Eastern Time, on July 28, 2023, or as soon thereafter as practicable. We hereby respectfully withdraw this acceleration request at this time. Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact Kevin Kelso at Weintraub Tobin, our counsel, at (916) 558-6110.
Very truly yours,
Adamis Pharmaceuticals Corporation
Show Raw Text
CORRESP 1 filename1.htm Adamis Pharmaceuticals Corporation 11683 El Camino Real, Suite 300 San Diego, CA 92103 July 28, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Adamis Pharmaceuticals Corporation Registration Statement on Form S-3 (No. 333-273233) Filed on July 13, 2023 Withdrawal of Request for Acceleration To Whom it May Concern: Adamis Pharmaceuticals Corporation (the "Company") hereby requests the withdrawal of our request for acceleration, dated July 26, 2023, of the effective date of the above referenced registration statement as amended (the “Registration Statement”) (File No. 333-273233) that was requested to become effective at 9:00 a.m. Eastern Time, on July 28, 2023, or as soon thereafter as practicable. We hereby respectfully withdraw this acceleration request at this time. Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact Kevin Kelso at Weintraub Tobin, our counsel, at (916) 558-6110. Very truly yours, Adamis Pharmaceuticals Corporation By: /s/ David J. Marguglio David J. Marguglio President